Kiniksa Pharmaceuticals International (KNSA) Proxy filing summary

Executive summary

• Annual General Meeting scheduled for May 29, 2026, with voting available online or in person.

• Shareholders are encouraged to review proxy materials and vote on key proposals affecting governance and compensation.

Voting matters and shareholder proposals

• Election of three Class II Directors to serve until the 2029 Annual General Meeting.

• Approval of PricewaterhouseCoopers LLP as UK statutory auditors until the 2027 AGM.

• Ratification of PwC as US independent registered public accounting firm for fiscal year ending December 31, 2026.

• Authorization for the Audit Committee to determine PwC's remuneration as UK statutory auditors.

• Advisory votes on the UK Statutory Directors' Annual Remuneration Report and executive compensation.

Board of directors and corporate governance

• Nominees for Class II Directors are Stephen R. Biggar, G. Bradley Cole, and Barry D. Quart.

• Directors to serve until 2029 or until successors are appointed or they resign.